NewAmsterdam Pharma publishes obicetrapib Alzheimer’s prevention research presentation
NewAmsterdam Pharma has released a research presentation on the use of its CETP inhibitor, obicetrapib, for Alzheimer's prevention. A Phase 3 substudy showed that obicetrapib reduced plasma p-tau217 after 12 months, particularly in APOE4/E4 carriers, and positively impacted other Alzheimer’s-related biomarkers. This research supports …